IRB #

STUDY00021884

Title

An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to investigate SDH-Mutant/Deficient Gastrointestinal Stromal cancer’s response to the drug Temozolomide (TMZ) to improve patient outcomes.

Medical Condition(s)

Gastrointestinal Stromal Tumor (GIST)-Advanced Succinate Dehydrogenase (SDH)- Mutant/Deficient Subtype

Eligibility Criteria

Patient is ≥ 12 years of age.
Pathologically confirmed SDH-mutant/deficient GIST

Age Range

12 - 100

Healthy Volunteers Needed

No

Duration of Participation

4 years

Minors Included

Yes

Contact

Knight Clinical Trials Office
trials@ohsu.edu
Phone: 503-494-2751

Sponsor

University of California, San Diego

Recruitment End

12/31/2025

Compensation Provided

No


Go Back